Danaher's stock plummeted 5.05% during intraday trading on Wednesday, following the release of the company's fourth-quarter earnings and forward guidance.
The life sciences firm reported Q4 adjusted earnings of $2.23 per share, beating the consensus estimate of $2.15, and revenue of $6.84 billion, slightly above expectations. However, the company's 2026 adjusted profit forecast of $8.35 to $8.50 per share was in line with analysts' average estimate of $8.42, disappointing investors who had hoped for stronger guidance.
Furthermore, Danaher anticipates first-quarter non-GAAP core revenue will increase only in the low-single digit percent range year-over-year, a modest outlook. The company also noted that academic and research demand remains muted, particularly in the U.S. and China, contributing to investor concerns about near-term growth prospects.
Comments